Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma)

Ann Oncol. 2012 Mar;23(3):805-807. doi: 10.1093/annonc/mdr633. Epub 2012 Jan 27.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Disease-Free Survival
  • Humans
  • Lymphoma, Follicular / drug therapy*
  • Lymphoma, Follicular / mortality
  • Lymphoma, Follicular / radiotherapy*
  • Mitoxantrone / administration & dosage
  • Mitoxantrone / adverse effects
  • Radioimmunotherapy / methods*
  • Vidarabine / administration & dosage
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives

Substances

  • Antibodies, Monoclonal
  • ibritumomab tiuxetan
  • Mitoxantrone
  • Vidarabine
  • fludarabine